Elamipretide: from study to decision to citation

A rare-disease path: a completed phase 3 trial whose primary endpoints were not met, the registry record behind it, and the U.S. accelerated approval for a different condition.

Also searched as SS-31, Bendavia, MTP-131, Forzinity. AI-assisted source verification, checked 2026-11-13. Human review: none recorded. Version 1.0.0 of this journey is frozen at its API address.

  1. 1 Registered study
  2. 2 Exact result
  3. 3 Regulatory decision
  4. 4 Copy the citation

1. Registered study

The original registry record is the primary source for what was planned, who was enrolled and what was posted.

2. Exact result

MMPOWER-3 (phase 3, double-blind, placebo-controlled)

Population
218 adults with genetically confirmed primary mitochondrial myopathy (109 elamipretide, 109 placebo)
Comparison
Elamipretide 40 mg once daily vs placebo, subcutaneous
Comparator
Placebo, subcutaneous once daily for 24 weeks
Endpoint
Co-primary: change from baseline in six-minute walk distance, and in the PMMSA total fatigue score
Time point
Week 24
Result
Primary endpoints not met. Difference in least-squares mean change, elamipretide minus placebo: six-minute walk distance -3.2 m (p=0.69); total fatigue score -0.07 (p=0.37).
Uncertainty
Six-minute walk distance difference: 95% CI -18.7 to 12.3 m. Total fatigue score difference: 95% CI -0.10 to 0.26 as printed in the abstract.
Source
PMID 37268435, doi:10.1212/WNL.0000000000207402, registry NCT03323749
Where each number sits (partly matched)
Neurology 2023 abstract (PubMed 37268435): participants, endpoints and both differences. ClinicalTrials.gov NCT03323749 results, primary outcome measure 1 (six-minute walk): week 24 mean change 15.330 m (SD 61.486, n=109) elamipretide and 17.386 m (SD 51.696, n=109) placebo. The registry reports unadjusted means, so it is consistent with the paper but does not reproduce the least-squares difference.

Limits of this record

  • Total fatigue score direction: lower is better on the 4 to 16 scale. The abstract prints the interval as -0.10 to 0.26 around -0.07; WPF reproduces it as printed.
  • The published figure and table locations in the full text (PMC10382259) were not read in this pass.
  • The trial was stopped after the double-blind part missed its primary endpoints. A post hoc genotype analysis exists (PMID 39574155) and is not part of this result.

Versioned record: /api/research/journey/elamipretide?version=1.0.0&resultId=mmpower-3-6mwt-24w

3. Regulatory decision

A regulator’s decision about one product. It is context, not scientific evidence, and does not transfer to other products or conditions.

FDA, United States: FORZINITY (elamipretide) injection, NDA 215244 (Stealth BioTherapeutics)

Indication
Barth syndrome in patients weighing at least 30 kg
Action type
Accelerated approval (new molecular entity, priority review)
Decision date
2025-09-19
Date checked
2026-11-13
Official source
FDA press announcement, 19 September 2025, "FDA Grants Accelerated Approval to First Treatment for Barth Syndrome"; openFDA Drugs@FDA record NDA215244 (ORIG-1, status AP, 2025-09-19, priority)
Limits
FDA states the approval rests on improved knee-extensor muscle strength, a measure reasonably likely to predict benefit, and requires a confirmatory randomized trial. It concerns Barth syndrome only. It says nothing about primary mitochondrial myopathy, the condition tested in MMPOWER-3.

No published WPF record for: United Kingdom; Canada; Australia; Japan; China. That says only that WPF has published none, not that no regulatory action exists. See the profile’s regulatory section or the regulatory matrix for Elamipretide, which shows every jurisdiction and where WPF has no published review.

Film

No SS-31 or elamipretide film is published. The proposed film route returns 404 and is not linked. This path works without it.

4. Copy the citation

Each citation names the release version and a versioned record address. If the evidence changes, the old address still returns the version you cited and links to the update.

MMPOWER-3 (phase 3, double-blind, placebo-controlled)

MMPOWER-3 (phase 3, double-blind, placebo-controlled). Elamipretide vs placebo. Primary source: https://doi.org/10.1212/WNL.0000000000207402 (PMID 37268435; NCT03323749). Cited from World Peptide Foundation, Research Journeys, version 1.0.0, result mmpower-3-6mwt-24w.

Page:
https://www.worldpeptidefoundation.org/research/journey/elamipretide#mmpower-3-6mwt-24w

Versioned record:
https://www.worldpeptidefoundation.org/api/research/journey/elamipretide?version=1.0.0&resultId=mmpower-3-6mwt-24w